We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
5,177.50 +10.00 (+0.19%) Dow Futures
38,300.00 +62.00 (+0.16%) Nasdaq Futures
18,217.50 +38.25 (+0.21%) Russell 2000 Futures
2,029.50 +9.70 (+0.48%) Crude Oil
85.39 -0.27 (-0.32%) Gold
2,369.60 -4.50 (-0.19%)
Teva Pharmaceutical Industries Limited (TEVA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 13.87 |
| Open | 13.70 |
| Bid | 13.06 x 3200 |
| Ask | 13.40 x 3200 |
| Day's Range | 13.07 - 13.70 |
| 52 Week Range | 7.09 - 14.47 |
| Volume | |
| Avg. Volume | 10,576,927 |
| Market Cap | 15.628B |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 27, 2017 |
| 1y Target Est | 15.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TEVA
Related Research
- Teva Pharmaceutical IndustriesAnalyst Report: Teva Phar Inds LtTeva Pharmaceutical Industries Ltd. is the world's largest generic pharmaceutical manufacturer, with roughly 76 billion tablets and capsules produced annually. The company has roughly 37,000 employees and over 53 manufacturing facilities across more than 33 countries. One of every 12 prescriptions in the U.S. is filled with Teva products.RatingFair ValueEconomic Moat19 days agoArgus Research
Business WireTeva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
TEL AVIV, Israel & PARSIPPANY, N.J., April 11, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients.
Business WireTeva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
TEL AVIV, Israel, April 09, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday, May 8, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Business WireNew Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
TEL AVIV, Israel & PARSIPPANY, N.J., April 06, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of eight studies from its LAI schizophrenia research program, including data evaluating UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults. The data were presented at the 2024 Congress of the Schizophrenia Inte
Business WireTeva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
TEL AVIV, Israel, & MADRID, April 04, 2024--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced they have entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications. Biosimilars show promising potential in providing more cost-effective altern
Motley Fool3 No-Brainer Stocks to Buy With $600 Right Now
A relatively modest amount of money can go a long way when it's put to work in top-tier businesses with abundant catalysts.
- Reuters
Biden and Senator Sanders to highlight efforts lower cost of asthma inhalers
U.S. President Joe Biden will host a White House event with U.S. Senator Bernie Sanders on Wednesday to highlight their efforts to cut the cost of inhalers for asthma suffers. Sanders and other lawmakers in January criticized four manufacturers of inhalers sold in the U.S. — AstraZeneca, Boehringer, Teva Pharmaceuticals (TEVA.TA), and GSK (GSK.L), — over prices that were much higher in the U.S. than in other countries. The Biden administration has also sought to crack down on what it calls falsely claimed patents in an effort to increase competition to lower inhaler costs.
- Reuters
UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to clear a path to launch cheaper generic versions of the medicine. The U.S. Court of Appeals for the Federal Circuit said that the last remaining J&J patent covering its Invega Sustenna may be invalid, sending the case back for a New Jersey federal court to reconsider. A J&J spokesperson said the company will "continue defending the intellectual property of Invega Sustenna."
ReutersTeva, Viatris win new chance to challenge J&J schizophrenia drug patent
(Reuters) -Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to clear a path to launch cheaper generic versions of the medicine. The U.S. Court of Appeals for the Federal Circuit said that the last remaining J&J patent covering its Invega Sustenna may be invalid, sending the case back for a New Jersey federal court to reconsider. A J&J spokesperson said the company will "continue defending the intellectual property of Invega Sustenna."
Business WireClinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
LONDON & BOSTON & TEL AVIV, Israel, April 01, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Launch Therapeutics, Inc., today announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248). Teva and Abingworth, a leading international life sciences investment group, part of global investment firm Carlyle (NASDAQ: CG), today also announced a strategic development funding agreement in which Abingworth provides Tev
ZacksBausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?
Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Morningstar Rating
Rating
Fair Value
Economic Moat
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| GILD Gilead Sciences, Inc. | |||
| BIIB Biogen Inc. | |||
| BMY Bristol-Myers Squibb Company | |||
| NVS Novartis AG | |||
| AMGN Amgen Inc. |
Similar to TEVA
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| VTRS Viatris Inc. | |||
| BHC Bausch Health Companies Inc. | |||
| TLRY Tilray Brands, Inc. | |||
| CGC Canopy Growth Corporation | |||
| ACB Aurora Cannabis Inc. |
Analyst Price Targets (8)
Upgrades & Downgrades
| Upgrade | JP Morgan: Underweight to Neutral | 3/8/2024 | |
| Upgrade | Piper Sandler: Neutral to Overweight | 2/12/2024 | |
| Maintains | Goldman Sachs: Neutral to Neutral | 2/5/2024 | |
| Maintains | Barclays: Overweight to Overweight | 2/5/2024 | |
| Maintains | Barclays: Overweight to Overweight | 1/29/2024 | |
| Upgrade | Jefferies: Hold to Buy | 1/23/2024 |
Company Profile
124 Dvora HaNevi’a Street
Tel Aviv 6944020
Israel
972 3 914 8213
https://www.tevapharm.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 35,001
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
